TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00622440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIJP (Arnebia Indigo Jade Pearl)
Description: Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 48 weeks.
Study: NCT04151303

Intervention type: PROCEDURE
Intervention: Cervical cerclage
Description: Cervical cerclage and cervical cerclage removal

Intervention type: PROCEDURE
Intervention: Cervical cerclage
Description: Cervical cerclage and cervical cerclage removal

Intervention type: PROCEDURE
Intervention: Cervical cerclage
Description: Cervical cerclage and cervical cerclage removal

Intervention type: PROCEDURE
Intervention: Cervical cerclage
Description: Cervical cerclage and cervical cerclage removal
Study: NCT03770988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Poziotinib
Description: Treatment with Poziotinib
Study: NCT03371043

Intervention type: OTHER
Intervention: users of analgesic medications
Description: Children and adolescents who are users of analgesic medications, 2012 to 2015
Study: NCT03333772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REAL-T Intervention
Description: Individualized lifestyle intervention conducted via internet-based videoconferencing and incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants will have approximately 6-10 sessions lasting about one hour each, over a 3-month period.
Study: NCT01895556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT05125588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)
Description: One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)
Description: One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
Study: NCT00891670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: 100mg twice daily for at least 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 100mg
Study: NCT01652534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill
Study: NCT00731302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin and meloxicam
Description: aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
Study: NCT03855488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard cognitive bias modification
Description: Participants will be asked to repeatedly listen to descriptions of ambiguous scenarios that resolve positively and answer one question following each scenario that reinforces the positive interpretation; participants will listen to 60 scenarios/day for 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery enhanced cognitive bias modification
Description: Participants will be asked to imagine themselves as though they are actively involved in the scenarios that they listen to. This condition will be required to answer two questions following each scenario; one that reinforces the positive interpretation and another that promotes engagement with imagery. Participants will listen to 60 scenarios/day for 7 days.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Control Condition
Description: Participants will be asked to listen to descriptions of neutral (i.e., non-emotional) scenarios. This condition will also be required to answer one comprehension question following each scenario. Participants will listen to 60 scenarios/day for 7 days.
Study: NCT03067714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with added synbiotics
Description: Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
Study: NCT01662570

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beverage Choice and Lifestyle Modification
Description: The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Education (NE)
Description: This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
Study: NCT00455182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
Study: NCT02231931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: single dose, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: single dose, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin
Description: fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin
Description: fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: single dose, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin
Description: fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: single dose, fasted
Study: NCT01032122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
Study: NCT02586740

Intervention type: PROCEDURE
Intervention: Pulmonary artery rehabilitation
Study: NCT00912795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Turkey
Description: 6-week smoking cessation program delivered via daily text messages~SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory.~Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day.~Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages).
Study: NCT00176917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, ATG
Description: Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Study: NCT02988895

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: episcleral brachytherapy
Description: The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
Study: NCT04014517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
Study: NCT03731676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed bearing total knee arthroplasty
Description: Fixed bearing total knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotating platform total knee arthroplasty
Description: Rotating platform total knee arthroplasty
Study: NCT04365608

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: standard laryngoscope with Macintosh blade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vie Scope laryngoscopy
Description: Vie Scope with dedicated bougie stylet
Study: NCT02476461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xiapex

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous needle fasciotomy
Study: NCT03860259

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Auriculotherapy cryopuncture device without nitrogen gas
Description: Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy cryopuncture device with nitrogen gas
Description: Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
Study: NCT01134055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo eye drops
Study: NCT03614520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol free Beer
Description: 250 mL of alcohol free beer (alcohol 0.0% vol)
Study: NCT01849042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebixa
Description: add-on of Ebixa oral pump already receiving donepezil with stable dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil

Intervention type: DRUG
Group type: OTHER
Intervention: donepezil
Study: NCT01134055

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab intravitreal injection
Description: Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
Study: NCT02918513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 1 - Exercise
Description: 1. Daily wellness element focusing on Exercise; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 2 - Mindfulness
Description: 2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 3 - Sleep Hygiene
Description: 3. Daily wellness element focusing on sleep hygiene; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 4 - Social Connectedness
Description: 4. Daily wellness element focusing on Social Connectedness; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 5 - Nutrition
Description: 5. Daily wellness element focusing on Nutrition; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 6 - Wellness Exercises
Description: 6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 7 - Motivational Messages
Description: 7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
Study: NCT00464776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Study: NCT06284135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Michl-stitch
Description: In the intervention group, a ventral fixation was performed by suturing the ventral bladder peritoneum to the plexus Santorini and from there to the right and left lateral endopelvic fascia (MICHL-stitch).
Study: NCT01558648

Intervention type: BEHAVIORAL
Intervention: Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log
Description: Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.

Intervention type: BEHAVIORAL
Intervention: Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log
Description: Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
Study: NCT04337918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NORS (Nitric Oxide Releasing Solution)
Description: NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.

Intervention type: DRUG
Group type: OTHER
Intervention: NORS (Nitric Oxide Releasing Solution)
Description: Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.~Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.
Study: NCT04737304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEN2293 (0.25% or 1.0% w/w) or matching placebo
Description: BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEN2293 (0.25% or 1.0% w/w) or matching placebo
Description: BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BEN2293 (0.25% or 1.0% w/w) or matching placebo
Description: BEN2293 and placebo will be administered as a topical ointment. Both ointments contain the same excipients; placebo ointment has been manufactured in the same way except for the addition of 0.25% and 1.0% (w/w) BEN2293.
Study: NCT00655200

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00392769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial Dose = 400 mg/m\^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m\^2 IV Over 60 Minutes.
Study: NCT00686686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
Study: NCT03644472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrate rich beetroot juice
Description: This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitrate depleted beetroot juice
Description: This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Study: NCT02566369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 (trifarotene) 50μg/g cream
Description: CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream applied once daily for 12 weeks
Study: NCT03644511

Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Prescribed by physician.

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Prescribed by physician.
Study: NCT02991976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen concentration
Description: Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen concentration
Description: Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
Study: NCT02900040

Intervention type: OTHER
Intervention: kidney transplantation